sozinibercept (OPT-302) / Opthea 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   45 News 
  • ||||||||||  Review, Journal:  Perspectives on the currently available pharmacotherapy for wet macular degeneration. (Pubmed Central) -  May 13, 2024   
    While current treatments for w-AMD have significantly advanced with the advent of anti-VEGF therapies, their limitations in terms of treatment burden and incomplete responses have spurred research into diverse alternative approaches. These innovative strategies offer hope for improving patient outcomes and reducing healthcare burdens, suggesting a promising future for w-AMD management.
  • ||||||||||  OPT-302 / Opthea
    Trial primary completion date:  ShORe: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) -  Nov 30, 2023   
    P3,  N=990, Recruiting, 
    These innovative strategies offer hope for improving patient outcomes and reducing healthcare burdens, suggesting a promising future for w-AMD management. Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  OPT-302 / Opthea, Lucentis (ranibizumab) / Roche, Novartis
    Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy ([Virtual]) -  Apr 29, 2022 - Abstract #ARVO2022ARVO_2572;    
    P2
    OPT-302 combination therapy was well tolerated, with greater improvements in BCVA and less retinal fluid compared to ranibizumab monotherapy in participants with symptomatic macular PCV. Larger studies of dual inhibition of VEGF-C/-D and VEGF-A for the treatment of PCV are warranted.
  • ||||||||||  Review, Journal:  Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Dec 16, 2021   
    Sustained-release anti-VEGF therapies include the ranibizumab Port Delivery System (in phase 3 studies), GB-102 (Phase 2b), OTX-TKI (phase 1), and Durasert (preclinical)...Genetic therapies in phase 1 studies include RGX-314 and ADVM-022, which introduce a viral vector that modifies the retina's cellular apparatus to create an anti-VEGF biofactory, potentially serving as a one-time treatment. Further investigation is warranted for drugs and delivery systems that hope to advance visual outcomes and reduce treatment burden of nAMD.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron
    Review, Journal:  Pipeline therapies for neovascular age related macular degeneration. (Pubmed Central) -  Oct 3, 2021   
    Those in the pipeline of VEGF targets include abicipar pegol (Abicipar; Allergan, Coolock, Dublin), OPT-302 (Opthea; OPTHEA limited; Victoria, Melbourne), conbercept (Lumitin; Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan), and KSI-301 (Kodiak Sciences, Palo Alto, CA)...Gene therapy present possible longer treatments options as well and are reviewed here. This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD.
  • ||||||||||  Journal:  Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. (Pubmed Central) -  Apr 10, 2021   
    Nine other upcoming agents have at least produced results in the 2A phase including intravitreal injections (KSI-301, OPT-302, RGX-314, ICON-1, and DE-122), depot (GB-102), drug reservoir (PDS), topical drops (PAN-90806), and oral formulations (AKST4290). We summarize all the newer molecules.
  • ||||||||||  OPT-302 / Opthea
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD (clinicaltrials.gov) -  Jan 21, 2020   
    P2,  N=366, Completed, 
    Recruiting --> Active, not recruiting | N=117 --> 153 Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> May 2019 | Trial primary completion date: Mar 2020 --> May 2019
  • ||||||||||  nesvacumab (REGN910) / Regeneron
    Journal:  Innovative therapies for neovascular age-related macular degeneration. (Pubmed Central) -  Nov 24, 2019   
    Sustained-release anti-VEGF treatments, to address treatment burden, include the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305. Similarly, genetic therapies, including RGX-314 and ADVM-022, aim to provide sustained anti-VEGF expression from the retina.
  • ||||||||||  OPT-302 / Opthea
    Trial completion date, Trial primary completion date, Combination therapy:  A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema (clinicaltrials.gov) -  Sep 19, 2019   
    P1b/2a,  N=117, Recruiting, 
    Similarly, genetic therapies, including RGX-314 and ADVM-022, aim to provide sustained anti-VEGF expression from the retina. Trial completion date: Jun 2019 --> Aug 2020 | Trial primary completion date: Mar 2019 --> May 2020
  • ||||||||||  OPT-302 / Opthea
    Enrollment closed, Combination therapy:  A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD (clinicaltrials.gov) -  Nov 28, 2018   
    P2,  N=366, Active, not recruiting, 
    Trial completion date: Jun 2019 --> Aug 2020 | Trial primary completion date: Mar 2019 --> May 2020 Recruiting --> Active, not recruiting